Abstract: Monoquaternary 2,16-bispiperidinylandrostane neuromuscular blocking derivatives having the formula: ##STR1## wherein R.sub.1 is ethyl;R.sub.2 is methyl or allyl; andX.sup.- is a pharmaceutically acceptable anion; or pharmaceutically acceptable salts thereof.

Abstract: Compounds having the formula: ##STR1## wherein R.sub.1 is H or an optionally substituted acyl group having 1-12 carbon atoms,R.sub.2 is H or an acyl group having 1-12 carbon atoms andR.sub.3 is C, N--CH.sub.3 or a direct bond;and mono- or bisquaternary ammonium compounds thereof and acid addition salts of the non- or mono-quaternary ammonium compounds. Process for the preparation of these compounds. Compositions comprising at least one of the above compounds as the active ingredient. The compounds are favorable neuromuscular blocking agents.

Abstract: This invention relates to novel mono- and bisquaternary ammonium derivatives of 5.alpha.-androstanes having the formula: ##STR1## wherein: R.sub.1 =H or alkyl (1-4 C);R.sub.2 and R.sub.3 each are alkyl (1-4 C) or form together with the N-atom a piperidino, pyrrolidino or morpholino group;R.sub.4 =O or H(.beta.OR.sub.5) andR.sub.5 =H or acyl derived from an organic carboxylic acid having 1-18, preferably 1-6 carbon atoms;the quaternarizing group being a saturated or unsaturated aliphatic hydrocarbon group having 1-4 carbon atoms the anion being halide; and acid addition salts of the monoquaternary compounds; and to pharmaceutical preparations containing one or more of said androstane compounds as active constituent.The compounds according to the invention are non-depolarizing neuromuscular blocking agents having very quick onset and recovery characteristics, a short duration of action and a favorable dissociation between muscle blocking and vagal blocking effects.

Abstract: New and pharmacologically useful pharmaceutically acceptable acid addition salts are disclosed for the 16.beta.-monoquaternary ammonium derivatives of either the 2.beta., 16.beta.-bis-piperdino-3.alpha., 17.beta.-dihydroxy-5.alpha.-androstane 3.alpha., 17.beta.-di-lower aliphatic esters or the 2.beta., 16.beta.-bis-piperidino-3.alpha.-hydroxy-5.alpha.-androstane-3.alpha.-lowe r aliphatic esters, which salts are surprisingly relatively stable in aqueous solutions, so that they provide stable aqueous injection preparations.

Abstract: New and pharmacologically useful pharmaceutically acceptable acid addition salts are disclosed for the 16.beta.-mono-quaternary ammonium derivatives of either the 2.beta., 16.beta.-bis-piperdino-3-.alpha., 17.beta.-dihydroxy-5.alpha.-androstane 3.alpha., 17.beta.-di-lower aliphatic esters of the 2.beta., 16.beta.-bis-piperidino-3.alpha.-hydroxy-5.alpha.-androstane-3.alpha.-lowe r aliphatic esters, which salts are surprisingly relatively stable in aqueous solutions, so that they provide stable aqueous injection preparations.